Skip to main content
Investors
Media
open in a new window
Contact Us
open in a new window
|
Search
open in a new window
Company
Science & Medicine
Patients
Responsibility
Careers
IR Home
Why Invest
Events & Presentations
Corporate Governance
Governance Documents
Executive Management
Board of Directors
Committee Composition
Contact the Board
Financials
Quarterly Results
Annual Reports
SEC Filings
Investor FAQs
Press Releases
Investor Contacts
Investor Emails Alerts
RSS Feeds
IR Home
Why Invest
Events & Presentations
Corporate Governance
Governance Documents
Executive Management
Board of Directors
Committee Composition
Contact the Board
Financials
Quarterly Results
Annual Reports
SEC Filings
Investor FAQs
Press Releases
Investor Contacts
Investor Emails Alerts
RSS Feeds
Close
Close
Investors
Company
Product
Research & Development
Patients
Partnerships
Careers
Close
Press Releases
Normal
Press Release RSS Feed (opens in new window)
Press release year list
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
December 3, 2020
Ironwood Pharmaceuticals Appoints Jay P. Shepard to Board of Directors
November 6, 2020
Ironwood Pharmaceuticals to Present at the 29th Annual Credit Suisse Healthcare Conference
November 5, 2020
Ironwood Pharmaceuticals Reports Strong Third Quarter 2020 Results and Increases Full Year 2020 Financial Guidance
November 5, 2020
Ironwood Pharmaceuticals Appoints Alexander Denner, Ph.D., to Board of Directors
October 22, 2020
Ironwood Pharmaceuticals to Host Third Quarter 2020 Investor Update Call
September 29, 2020
Ironwood to Discontinue IW-3718 Development Program Following Results from Planned Efficacy Assessment
September 2, 2020
Ironwood Pharmaceuticals to Participate in Upcoming September Investor Conferences
August 6, 2020
Ironwood Pharmaceuticals Reports Second Quarter 2020 Results; Delivered GAAP Net Income of $25 Million and Adjusted EBITDA of $33 Million
July 23, 2020
Ironwood Pharmaceuticals to Host Second Quarter 2020 Investor Update Call
July 21, 2020
Ironwood Announces Updates Designed to Strengthen IW-3718 Phase III Program for Refractory Gastroesophageal Reflux Disease (GERD)
May 27, 2020
Ironwood and AbbVie Report Top-line Phase II Data for MD-7246 in Patients with Abdominal Pain Associated with Irritable Bowel Syndrome with Diarrhea (IBS-D)
May 6, 2020
Ironwood Pharmaceuticals Reports First Quarter 2020 Results and Provides Update on Impact of COVID-19 Pandemic
April 28, 2020
Ironwood and Allergan Receive Notices of Allowance for Patent Applications Covering 72 mcg Dose of LINZESS® (linaclotide)
April 16, 2020
Ironwood Pharmaceuticals to Host First Quarter 2020 Investor Update Call
March 26, 2020
Ironwood Pharmaceuticals Provides Update on Impact of COVID-19
March 14, 2020
A message to our healthcare providers, patients and other partners during COVID-19
Download
PDF format download (opens in new window)
February 26, 2020
Ironwood Pharmaceuticals Announces Publication of Positive IW-3718 Phase IIb Data in Gastroenterology
February 25, 2020
Ironwood Pharmaceuticals to Present at Upcoming March Investor Conferences
February 19, 2020
Ironwood Pharmaceuticals to Present at SVB Leerink Global Healthcare Conference
February 13, 2020
Ironwood Pharmaceuticals Reports Strong Fourth Quarter and Full Year 2019 Results, Exceeding Full Year 2019 Guidance; Provides Full Year 2020 Guidance
January 30, 2020
Ironwood Pharmaceuticals to Host Fourth Quarter and Full Year 2019 Investor Update Call
January 22, 2020
Ironwood and Allergan Announce Settlement with Teva Resolving LINZESS® (linaclotide) Patent Litigation
January 6, 2020
Ironwood and Allergan Announce Settlement Resolving LINZESS® (linaclotide) Patent Litigation
January 2, 2020
Ironwood Pharmaceuticals to Present at J.P. Morgan Healthcare Conference